The pharmacokinetics of risperidone in humans: a summary
- PMID: 7520903
The pharmacokinetics of risperidone in humans: a summary
Abstract
Risperidone is rapidly and completely absorbed after oral administration; less than 1% is excreted unchanged in the feces. The principal metabolite was found to be 9-hydroxyrisperidone. Hydroxylation of risperidone is subject to the same genetic polymorphism as debrisoquine and dextromethorphan. In poor metabolizers the half-life of risperidone was about 19 hours compared with about 3 hours in extensive metabolizers. However, becuase the pharmacology of 9-hydroxyrisperidone is very similar to that of risperidone, the half-life for the "active fraction" (risperidone +9-hydroxyrisperidone) was found to be approximately 20 hours in extensive and poor metabolizers. We found that risperidone exhibited linear elimination kinetics and that steady state was reached within 1 day for risperidone and within 5 days for the active fraction.
Similar articles
-
Absorption, metabolism, and excretion of risperidone in humans.Drug Metab Dispos. 1993 Nov-Dec;21(6):1134-41. Drug Metab Dispos. 1993. PMID: 7507814
-
Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.Clin Pharmacol Ther. 1993 Sep;54(3):257-68. doi: 10.1038/clpt.1993.146. Clin Pharmacol Ther. 1993. PMID: 7690693
-
The metabolism and excretion of risperidone after oral administration in rats and dogs.Drug Metab Dispos. 1994 Jan-Feb;22(1):129-38. Drug Metab Dispos. 1994. PMID: 7512019
-
Pharmacological profile of risperidone.Can J Psychiatry. 1993 Sep;38 Suppl 3:S80-8. Can J Psychiatry. 1993. PMID: 7504573 Review.
-
Brief comparison of the pharmacokinetics and pharmacodynamics of the traditional and newer antipsychotic drugs.Am J Health Syst Pharm. 1995 Feb 1;52(3 Suppl 1):S15-8. doi: 10.1093/ajhp/52.3_Suppl_1.S15. Am J Health Syst Pharm. 1995. PMID: 7538435 Review.
Cited by
-
Plasma dopa decarboxylase activity in treatment-resistant recent-onset psychosis patients.Ther Adv Psychopharmacol. 2019 Sep 6;9:2045125319872341. doi: 10.1177/2045125319872341. eCollection 2019. Ther Adv Psychopharmacol. 2019. PMID: 31523419 Free PMC article.
-
Serum concentrations of paliperidone versus risperidone and clinical effects.Eur J Clin Pharmacol. 2010 Aug;66(8):797-803. doi: 10.1007/s00228-010-0812-7. Epub 2010 Apr 1. Eur J Clin Pharmacol. 2010. PMID: 20358189
-
Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.J Pharmacokinet Pharmacodyn. 2007 Apr;34(2):183-206. doi: 10.1007/s10928-006-9040-2. Epub 2006 Nov 29. J Pharmacokinet Pharmacodyn. 2007. PMID: 17136449 Clinical Trial.
-
Risperidone is not only a prodrug: psychosis induced by medication switch from risperidone to paliperidone - a case report.Eur J Hosp Pharm. 2023 Jul;30(4):e20. doi: 10.1136/ejhpharm-2021-002901. Epub 2021 Nov 16. Eur J Hosp Pharm. 2023. PMID: 34785566 Free PMC article.
-
New atypical antipsychotics. Experience and utility in the elderly.Drugs Aging. 1998 Feb;12(2):115-27. doi: 10.2165/00002512-199812020-00004. Drugs Aging. 1998. PMID: 9509290 Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources